B

Bradenton Research Center | Bradenton, FL

Research site
(Unclaimed)
Location
3924 9th Avenue West, Bradenton, Florida, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

7 of 46
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study to Evaluate Efficacy and Safety of Intravenous ACU193 in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

The primary purpose of this study is to evaluate the efficacy of ACU193 infusions administered once every four weeks (Q4W) in slowing cognitive and f...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: ACU193

The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discont...

Active, not recruiting
Alzheimer's Disease
Drug: Aducanumab

Primary Objective:To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe...

Enrolling
Sjogren's Syndrome
Drug: Dazodalibep
Drug: Placebo

This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. Th...

Active, not recruiting
Early Alzheimer's Disease
Drug: Experimental: ALZ-801
Drug: Placebo Comparator: Placebo

This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2...

Enrolling
Agitation in Patients With Dementia of the Alzheimer's Type
Drug: AVP-786

This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 ge...

Not yet enrolling
Early Alzheimer's Disease
Drug: Experimental: ALZ-801

Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Re...

Enrolling
Multiple Sclerosis
Drug: IMU-838 tablets
Drug: Placebo matching IMU-838 tablets

Trial conditions

Alzheimer Disease (25 trials)
Seizures (5 trials)
Dementia (3 trials)
Diabetic Neuropathies (3 trials)
Multiple Sclerosis (3 trials)
Partial Epilepsies (3 trials)
Psychomotor Agitation (3 trials)
Sclerosis (3 trials)
Diabetes Mellitus (2 trials)
Epilepsy (2 trials)

And 30 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems